Knocking down hnRNPD in CML cells results in down-regulation of PBX1 expression, which inhibits CML cell growth and lead to sensitization of CML cells to imatinib. This evidence concerns the gene PBX1 and chronic myelogenous leukemia, BCR-ABL1 positive.